SPN-821 not checked

Supernus Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling”In the company’s words, NCT07226661 on ClinicalTrials.gov
Tested for
Major Depressive Disorder (MDD)
Main trialPhase 2
“This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder”In the company’s words, NCT07226661 on ClinicalTrials.gov

Other drugs for Major Depressive Disorder (MDD)

All 36 drugs for Major Depressive Disorder (MDD)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2026 Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SPN-821

Following is part of Solo: you see every change to SPN-821 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in